[Bevacizumab in thoracic oncology: results and practical aspects].
Fiche publication
Date publication
juin 2013
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MENNECIER Bertrand
Tous les auteurs :
Dansin E, Cousin S, Lauridant G, Mennecier B
Lien Pubmed
Résumé
Bevacizumab (Avastin((R))) is the first antiangiogenic therapy approved in non-small cell lung cancer (NSCLC). It is also currently the only agent in this family approved in NSCLC. This review focuses on results of clinical trials assessing bevacizumab in thoracic oncology. It also provides to clinicians practical advices for its prescription.
Référence
Rev Pneumol Clin. 2013 Jun;69(3):159-69